14-06-2017 to 16-06-2017
Introduction to Healthcare Business Development is a three day training… more info / booking...
Sharon Finch is the CEO of Medius Associates, a specialised pharma business development consultancy group. Sharon has more than 30 years proven experience in business development having worked in-house at the Wellcome Foundation, Medeva plc and Ono Pharmaceutical Co. Ltd. prior to founding Medius in 1994.
Sharon is Editor of the Business Development & Licensing Journal and the Course Director for the MSc in Pharmaceutical Business Development and Licensing run at the University of Manchester. She is also a past Chairman of the UK Pharmaceutical Licensing Group Ltd, a past President of the European PLG Council and a member of the LES Healthcare Committee in the UK.
Jill has over 26 years’ experience in the biopharmaceutical, healthcare and drug delivery industries, combining broad commercial experience with a strong scientific background. Her key skills and achievements include:
Jill has a PhD in Genetics and spent five years in molecular biology research at the Universities of Edinburgh and Oxford before joining Delta Biotechnology in 1987, where she held various R&D and project management positions covering a range of biopharmaceutical products and technologies. On leaving Delta in 1993, Jill co-founded a consultancy business specialising in the biopharmaceutical industry where she was involved in projects for US and European clients.
In 1996, Jill joined Andaris in business development and during the next 4 years was involved in two separate acquisitions; Andaris was first acquired by Quadrant Healthcare and then the enlarged Quadrant Group was acquired by Elan Corporation, where she was Director of Business Development. Throughout this time, Jill was involved in numerous licensing and product and technology divestment activities and finalised a range of deals on early stage products and technology platforms.
In 2003 Jill joined pSivida, an Australian NASDAQ-listed company, where she was Commercial Director with a broad range of business responsibilities focused on generating value from pSivida’s BioSilicon™ technology for drug delivery and product development applications. Since leaving pSivida in early 2007, Jill has been a business development consultant working for numerous international clients. During this time she has been involved in a range of transactions. Until recently she was a Board Director of Warwick Effect Polymers and its part time VP of Business Development, playing a leading role in the company’s acquisition.
Alan Warrander has over 25 years wide-ranging experience in the Pharmaceutical Industry having worked both in Pharma companies and as a Consultant.
Until the end of 2007, Alan was Senior Vice President, Life Sciences at Wood Mackenzie, the global consultancy firm where he provided consultancy advice and expert scientific opinion to Pharma, Biotech companies, Finance groups and Law firms primarily in the areas of Partnering, Due Diligence and Strategic Planning. Alan was also responsible for the production of a number of Expert Reports on a range of companies in support of potential AIM flotations.
His academic background is in Xenobiotic Metabolism, with a PhD from Birmingham University and a BSc in Chemistry and Biochemistry from St Andrews. He is a recognised conference speaker having being invited to present on various aspects of Partnering and Due Diligence.
Roger Davies works as a consultant in pharmaceutical licensing and business development. Having personally completed over 80 deals he specialises in valuations, deal structuring and negotiating licensing and acquisition deals. He is a former Chairman of the UK Pharmaceutical Licensing Group, the professional association of licensing and business development executives and is the Finance module leader for the Business Development MSc at the University of Manchester.
He was formerly the Group Director of Licensing and Business Development at Bioglan Pharma Plc where he was responsible for the global licensing and acquisition of products and drug delivery technologies as well as European distributors and the Legal department. Prior to joining Bioglan in 2000, Roger was employed at Mundipharma International for 10 years as Director of International Business Development where he was responsible for product and company acquisitions/disposals, inward and outward product licensing and European pricing.
Roger has a Masters degree in Economics.
Since February 2013, Dr. Klaus Maleck is Chief Executive Officers at TETEC AG, a market leader in the field of regenerative medicine.
Between April 2007 and January 2013, Dr Klaus Maleck was member of the Evotec Management Board as Chief Financial Officer and as EVP Corporate development, assuming responsibility for strategic development, focusing on M&A transactions and licensing. He signs responsible for several acquisitions and divestitures, product development out-licensing deals and a Nasdaq listing, among others. Prior to Evotec, he built up BioGeneriX AG, which he co-founded in 2000. In his function as Chief Financial Officer and Vice President Business Development, he was responsible for in-licensing advanced development candidates and for building a product pipeline of up to six clinical development programmes and several non-clinical projects. He secured financing through extensive partnering and closed several co-marketing deals with big pharma, and thus was able to considerably increase the shareholder value. Dr Maleck worked as a Senior Consultant at McKinsey & Co. from 1999 to 2000, and as a Scientist in the genomics field at Novartis, Inc. from 1996 to 1999. He was also a lecturer at the Mannheim University in Economics, the pharma licensing club and other institutions and is a tutor at Manchester University.
Dr Maleck received his Ph.D. in biotechnology from the Max-Planck-Institute Cologne, and holds a Masters degree in biotechnology of the Ecole Supérieure de Biotechnologie in Strasbourg France. In addition, he received post-graduate training in economics at Ashridge College in the UK, and at Swiss-based Educatis University, where he earned an MBA degree. He was a fellow of the Conseil Régional d’Alsace, the Daimler-Benz-Foundation and the German Scholarship Foundation.
Stephen is a Partner in Olswang’s Intellectual Property Group and leads its Life Sciences practice.
Stephen advises clients on both contentious and non-contentious intellectual property matters including patents, trade marks, trade secrets and copyright. He represents and advises a broad range of clients in relation to the protection, exploitation and enforcement of their intellectual property rights.
He has significant experience representing those clients within the life sciences and technology fields on both contentious and non-contentious matters. Stephen has represented clients in significant patent litigation disputes including Boston Scientific and Lonza Biologics. He also has considerable experience in commercial transactions within the life sciences industry. He advises on research & development, licensing, disposals, acquisitions and due diligence activities and has acted on behalf of clients in highly successful and publicised collaboration transactions. In connection with his life sciences practice Stephen also advises clients on UK and EU regulatory matters.
Stephen is recognised for his expertise and has been described by Legal 500 as “astute” and “highly knowledgeable”. Stephen is currently an examiner for one of the papers for CIPA (Patent Attorneys) and ITMA (Trade Mark Attorneys) students and has given many external lectures on topics including IP audits, co-marketing and co-promotion agreements, research and development contracts and injunctions. He is also a tutor on the PLG’s Masters degree.
Paul spent the early part of his career as an in-house lawyer for Smith Kline and Merck Sharpe & Dohme. He is a specialist in the commercial business development and regulatory aspects of the above industries.
He has written and lectured extensively in legal issues for the sector including on licensing and outsourcing within the field. His publications include six report-length papers for the FT, Bridgehead and Legalease.
He is also Head of the Editorial Board of Health Science Law and Business (Legalease). He is on the Legal Issues Committee of the ABHI and has been a member of a local 7 Ethics Committee for five years.
Peter Cozens has worked for more than 27 years in the pharmaceutical industry. He is a scientifically-qualified commercial development professional with broad international experience in both the biotechnology and conventional pharmaceutical sectors of the industry. Experienced in all facets of identifying, negotiating and managing third party agreements in all major territories to facilitate strategic business expansion. Additional responsibility in managing Patents and Trademark functions, including overseeing multinational patent litigation, many cases of which gave rise to seminal patent law, has provided valuable experience in contractual and intellectual property law. Experience also includes management of an export function responsible for sales outside Europe and the US and responsibility for strategic marketing/business information. A molecular geneticist by training on completion of his PhD, in 1978 Peter joined Ciba-Geigy (now Novartis) in Basel, Switzerland as a research scientist. In 1981 he moved to Wellcome Biotechnology Ltd. to work as a senior scientist in Molecular Biology and became leader of Wellcome’s cytokine programme. From 1987 to 1991, whilst still at Wellcome, he worked with Group Patents and Agreements on both patent litigation and licensing activities.
In 1991 he joined Medeva PLC where he became Executive Vice President, Business Development and Intellectual Property and a member of Medeva’s Executive Management Committee. Peter’s major achievement during this period was the building of Medeva’s development pipeline. He was responsible for a series of in-licensing and out-licensing deals and acquisitions including partnerships with Janssen, Connetics Corporation, Targeted Genetics, Peptide Therapeutics, SmithKline Beecham, ML Labs, Aviron, Mayo Medical Ventures, Eurand and Chiroscience. Peter also piloted the Biogen v. Medeva patent case through several courts culminating in the landmark House of Lords decision on the scope of patent claims. He is Chairman of the Intellectual Property Advisory Committee of the UK BioIndustry Association and a Non-Executive Director of Eden BioPharma Limited.
Tim qualified as a Barrister in 2000 and his practice now covers all aspects of UK and European intellectual property law, competition law, biotech commercialisation and bio-regulatory matters, as well as more general commercial litigation. His experience includes dealing with matters before the High Court, the Technology and Construction Court and the Court of Appeal in the UK, as well as the European Patent Office and OHIM.
Prior to becoming a barrister Tim took a B.Sc.(Hons) in Molecular Biology & Biochemistry, at Durham University and a Ph.D. in Biochemistry at the University of Cambridge; where he carried out research into the insect receptor proteins for Bacillus thuringiensis delta-endotoxins.
Anne has worked in the pharmaceutical industry for 24 years in both the CRO sector and for several large pharma companies, having obtained a B.Sc. (Hons) in Agricultural Biochemistry and Nutrition from Newcastle University and an MPhil in Computer modelling of radionuclides in sheep from Nottingham University. Most of her time in the pharmaceutical industry has been spent in clinical development and project leadership roles in R&D. Anne’s project experience covers cardiovascular, inflammation and oncology therapeutic areas and she has a special interest in paediatric programmes having worked on paediatric programmes in cardiovascular, metabolic and oncology therapeutic areas.
Anne also has a strong interest in development of people and was involved in the development of an MSc course in Clinical Data Management. She has also held several External Examiner posts with universities for both BSc and MSc programmes in the pharmaceutical industry.
Mark Wilson has worked for GlaxoSmithKline and its predecessor companies for 16 years and has experience of both manufacturing and development in relation to primary processing, secondary processing and large-scale antibiotic production.
He has worked in a licensing role for several years and has negotiated and managed hundreds of collaborative development deals for a technology incubator within GSK that is focussed on novel secondary processing approaches. In relation to compound licensing, he has been an expert pharmaceutics reviewer on several due diligence visits, has co-drafted internal guidelines on negotiation approaches with regard to manufacturing and pre-clinical development activities, and has advised on such matters on approximately 30 major compound licence negotiations.
Tel: 07850 942806